ArticleCancer cell2021
The NCI-MATCH: A National, Collaborative Precision Oncology Trial for Diverse Tumor Histologies.
Article in Cancer cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.The Cochrane database of systematic reviews · 2025Pooled it
- Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial.Nature medicine · 2025Trial
- Network-Integrated Platform for Clinical Trial Navigation from the New South Wales Early Phase Clinical Trials Alliance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- The nationwide survey of Japanese public opinion about off-label use of anticancer drugs recommended by comprehensive genomic profiling.International journal of clinical oncology · 2025Review
- First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors: 1-Year Follow-Up of the FIRST-Dx Study.Cancer science · 2025Article
- Personalized High-Resolution Genetic Diagnostics of Prostate Adenocarcinoma Guided by Multiparametric Magnetic Resonance Imaging: Results of a Pilot Study.International journal of molecular sciences · 2025Article
- Tumor-Agnostic Therapies in Practice: Challenges, Innovations, and Future Perspectives.Cancers · 2025Review
- Molecular pathology of lymphoma and its treatment strategies: from mechanistic elucidation to precision medicine.Frontiers in immunology · 2025Review
- Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.Nature communications · 2024Article
- Aqueous Humor Liquid Biopsy as a Companion Diagnostic for Retinoblastoma: Implications for Diagnosis, Prognosis, and Therapeutic Options: Five Years of Progress.American journal of ophthalmology · 2024Observational
- Basket Trials: Past, Present, and Future.Annual review of cancer biology · 2024Article
- DNA Quantity and Quality Comparisons between Cryopreserved and FFPE Tumors from Matched Pan-Cancer Samples.Current oncology (Toronto, Ont.) · 2024Article
- Computational repurposing of oncology drugs through off-target drug binding interactions from pharmacological databases.Clinical and translational medicine · 2024Article
- Molecular and modular intricacies of precision oncology.Frontiers in immunology · 2024Review
- Revolutionizing Cancer Treatment: Harnessing the Power of Biomarkers to Improve Patient Outcomes.Journal of the advanced practitioner in oncology · 2023Review
- Article
- Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).Frontiers in oncology · 2023Article
- Somatic Mutations in Breast Cancer: The Tip of the Iceberg.Journal of breast cancer · 2022Article
- The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.International journal of molecular sciences · 2022Review
- Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The NCI-MATCH is a national master protocol trial, published in the Journal of Clinical Oncology, in which diverse tumors are sequenced and patients assigned to treatment. The trial demonstrates the feasibility of identifying rare and common actionable genetic alterations and underscores the strength of academic/community partnerships for improving trial access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.